RELATED STUDY

A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo

Key Findings:  Using mixed lymphocyte reaction (MLR) as a model of organ and skin graft rejection in mice found that exposure to CB2 selective agonists prolongs skin graft rejection time, and presents a potential therapeutic target in organ transplant rejection prevention and autoimmune conditions.

Type of Study:  Animal Study

Study Result:  Positive

Study Location(s):  United States

Year of Pub:  2021


Cannabinoids Studied:  Tetrahydrocannabinol (THC), O-x Synthetic Cannabinoids, 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified)

Phytocannabinoid Source:  Not Applicable

Receptors Studied:  CB1, CB2

Ligands Studied:  Anti-inflammatory cytokines, Pro-inflammatory cytokines

Route of Administration:  In vitro



Link to study